1. Masur K, Thevenod F, Zanker KS (eds): Diabetes and cancer, Epdimological Evidence and Molecular Links,
Front pathophysiology of diabetes Mellitus Type 2: Roles of Obesity, Insulin resistance and cell dysfunction
diabetes, Basel, Karger, 2008, vol 19, pp 1-18.
2. Stern MP: Diabetes and cardiovascular disease: the “common soil” hypothesis. Diabetes 44: 369–374, 1995.
3. Jarrett RJ, Shipley MJ: Type 2 (non-insulin-dependent) diabetes mellitus and cardiovascular disease: putative
association via common antecedents— further evidence from the Whitehall Study. Diabetologia 31:737–740, 1988.
4. Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med 340:115–126, 1999
5. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, Azambuja MI, Tracy RP, Heiss G,
for the ARIC Investigators: Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis
Risk in Communities study): a cohort study. Lancet 353:1649–1652, 1999
6. Tessari P, Kiwanuka E, Millioni R, Vettore M, Puricelli L, Zanetti M, Gucciardi A, Tosolini M, Cogo P, Carnielli
V, Tiengo A, Barazzoni R. Albumin and fibrinogen synthesis and insulin effect in type 2 diabetes patients with
normoalbuminuria. Diabetes care 2006 Feb; 29(2): 323-8.
7. Taj Mohammad, Akbar Khoja, Khem A Karira, Abdur Harman. Comparison of Plasma Protein Concentration and
Hematological parameters in type-1 and type-2 Diabetics of short and long duration. Med channel Oct-Dec 2001;
7(4); 51-4.
Parameter
Controls (n=50)
Mean ±SD
Cases (n=50)
Mean ±SD
P-value
PLASMA
Glucose Fasting
80.100−+7.399 158.54 <0.0001
PLASMA glucose PgBS 118.38−+14.000 <0.0001
PLASMA TOTAL
PROTEIN
7.672−+0.3071 <0.0007
PLASMA ALBUMIN 4.492−+0.4040 <0.0001
PLASMA FIBRILOGEN 0.2314−+0.008636 <0.0001
683
Indian Journal of Basic & Applied Medical Research; June 2013: Issue-7, Vol.-2, P. 679-685
681
www.ijbamr.com P ISSN: 2250-284X E ISSN: 2250-2858
8.Coppola G, Corrado E, Tantillo R, Vitale G, Lo Coco L, Novo S. Increased levels of C-reactive protein and
fibrinogen influence the risk of vascular events in patients with NIDDM. Int J Cardiol. Jan 4; 106(1): 16-20.
9. I.D.P.WOOTON-Microanalysis in medical Biochemistry,5th.edi,CHURCHIL,LININGSTONE , Edinbergh and
London 1974,157-158.
10. Laurell, C, -B., Composition and variation of the gel electrophoretic fractions of plasma, cerebrospinal fluid and
urine, Seand J. Clin. Lab. Invest., 29 (suppl. 124), 71, 1972.
11. Laurell, c, -b., Is Eletrophoretic analysis of plasma proteins becoming out-dated, Scand. J. Clin. Lab. Invest., 30,
233, 1972.
12. Kawai, T., Clinical Aspects of the Plasma Proteins, J. B. Lippincott, Philadelphia, 1973, section IV.
13. Sun, T., Lien, Y. Y.,and Gross, S., Clinical application of a high-resolution electrophoresis system, Ann. Clin.
Lab. Sci., 8, 219, 1978.
14. Ritchie, R. F., Automated nephelometric analysis apecific serum proteins: clinical applications, in Protides of the
Biological Fluids (21st colloquium 1973), Peeters, H., Ed., Pergamon Press, Oxford, 1974, 593.
15. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, Azambuja MI, Tracy RP, Heiss
G: Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities
study): a cohort study. Lancet 353:1649 –1652, 1999.
16. Pierpaolo De Feo, t Margaret Gan Gaisano, and Morey W. Haymond Differential effects of insulin deficiency
on albumin and Fibrinogen synthesis in humans. The American society for J. Clinical Investigation, Inc. Volume 88,
September 1991, 833-840.
17. Boulge, D., Coudon, B., and Giraudet, P., Interet diagnostique due profil proteique, in Procedings of the
technicon Colloquium en Automated Measurement of proteins by Immunonephelometry. Technicon, Paris, 1973,1.
18. Killing’s worth, L.M., An automated approach to the preparation of plasma protein profiles, in protrudes of the
Biolgical Fluids (23rd colloquium 1975) Peeters, H., Ed.,Pergamon Press, Oxford, 1976, 291.
19. Ritchie, R. F., What abnormal serum proteins may indicate, Patient Care, May 2, 1974.
20. Festa, A., D’Agostino, Jr, R., Tracy, R. P. and Haffner, S.M.(2002) Elevated levels of acute phase proteins and
plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis
study. Diabetes 51, 1131–1137
21. Pickup, J. C. (2004) Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes.
Diabetes Care 27, 813–823
22. Sjoholm, A. and Nystrom, T. (2006) Inflammation and the etiology of type 2 diabetes. Diabetes Metab. Res.
Rev. 22,4–10
23. Ceriello A, Giacomello R, Stel G, et al. 1995 Hyperglycemia-induced thrombin formation in diabetes. The
possible role of oxidative stress. Diabetes. 44:924 –928.
684
Indian Journal of Basic & Applied Medical Research; June 2013: Issue-7, Vol.-2, P. 679-685
682
www.ijbamr.com P ISSN: 2250-284X E ISSN: 2250-2858
24. Ritchie DG, Levy BA, Adams MA, Fuller GM. 1982 Regulation of fibrinogen synthesis by plasmin-derived
fragments of fibrinogen and fibrin: an indirect feedback pathway. Proc Natl Acad Sci USA. 79:1530 –1534.
25. Kannel WB, D’Agostino RB, Wilson PW, Belanger AJ, Gagnon DR. 1990 Diabetes, fibrinogen and risk of
cardiovascular disease: the Framingham experience.Am Heart J. 120:672– 676.
26. Missov RM, Stolk RP, van der Bom JG, et al. 1996 Plasma fibrinogen in NIDDM. The Rotterdam Study.
Diabetes Care. 19:157–159.
27. De Feo P, Gan Gaisano M, Haymond MW. 1991 Differential effects of insulin deficiency on albumin and
fibrinogen synthesis in humans. J Clin Invest.88:833– 840.
28. Laurell, C.B., Electrophoresis, specific protein assays, or both in measurement of plasma proteins, clin, chem.
(Winston-Salem, N.C.), 19,99,1973.
29. Alper, C.A., Plasma protein measurements as a diagnostic aid, N. Engl. J. Med., 291, 287, 1974.
30. Killingsworth, L. M., A report format for serum proteins, Clin, Chem. (Winson-Salem, N.c.), 24, 728, 1978.
31. Ganda OP, Arkin CF. Hyperfibrinogenemia, an important risk factor for vascular complications in diabetes.
Diabetes Care 1992; 15: 1245-50.
32. Collier A, Rumley A, Rumley AG et al. Free radical activity and hemostatic factors in NIDDM patients with and
without microalbuminuria. Diabetes 1992; 41: 909-13.
33. Schmitz A, Ingerslev J. Haemostatic measures in type 2 diabetic patients with microalbuminuria. Diabet Med
1990; 7: 521-5.
Thank you for copying data from http://www.arastirmax.com
